

SEQUENCE LISTING

<110> ACADIA PHARMACEUTICALS INC.

<120> Use of the Lipoxin Receptor, FPRL1, as a Tool for Identifying Compounds Effective in the Treatment of Pain and Inflammation

<130> 65167.00023

<140> 10590001

<141> 2007-05-25

<150> 10/590,001

<151> 2006-08-17

<150> PCT/US2004/036952

<151> 2004-11-04

<160> 2

<170> PatentIn version 3.3

<210> 1

<211> 2631

<212> DNA

<213> human neutrophils and monocytes *Homo sapiens*

<400> 1

ggcacagagga acaacctatt tgcaaagttg ggcacaacat tcctgcctga caggaccatg 60

gacacaggtt gtagagatag agatggctct ggctgtgcat tcagcagatt ctgttagatag 120

aattaattag gacttggatg ggattgtggt gagagaaagt gaaatgaaag ataagttcta 180

gtttggaaagt tttaacaact gaatgtttaa actcaaatac acacaaaata ttggaagagt 240

ggcagggttg ggaggatgag acaatcaact gtttggttga gccacgttag gtttggaaatg 300

tctacgggat cccgtgggga gaggttatatac cagactggag caccagagag aggccaaggc 360

tgatagttta gatgaaaaga gagcatgata tttaagccc tgagactgga taatatcacc 420

tatagaaaaga ctatatacatac ataagagagg tggggaaacaa gtaaaagctg cgggacactc 480

ctaaattttag agtcaaattt agagcagaaaa atactagcaa agggactga aaagcggtgg 540

ccaattgagc ttcaaatttca agtggaaatgt tggtgtgtgt acatttatca tctcatggca 600

caggaaaaac gtgatataag gagaaggaag cgatccatg ggaagaagag atccaatggaa 660

tcctctatca cgaagatatt gagataagaa ccaatatggaa tttgcaccca ctgcattgc 720

agccttgagg tcataaggcat cctcaggaaaa atgcaccagg tgctgtggc aagatggaaa 780

ccaacttctc cactcctctg aatgaatatg aagaagtgtc cttgagtcgtg ctggctacac 840

tgttctgcgg atcccccatttgggtgtgt tggggtcacc tttgtctcg gggtcctggg 900

caatgggctt gtatctggg tggctggatt ccggatgaca cgcacagtca ccaceatctg 960
ttacctgaac ctggccctgg ctgacttttc tttcacggcc acattaccat tcctcattgt 1020
ctccatggcc atgggagaaa aatggccttt tggctggttc ctgtgaatg taattcacat 1080
cgtggtggac atcaacctct ttggaaagtgt ctcttgatt ggttcattg cactggaccg 1140
ctgcatttgcgtcact cagtcgtggc ccagaaccac cgcaactgtga gtctggccat 1200
gaaggtgatc gtccggacatt ggattcttgc tctagtcctt accttgcag tttcccttt 1260
tttgactaca gtaactatta caaatgggg cacatcatgt acttcaact ttgcattctg 1320
gggtggcacc cctgaggaga ggctgaaggt ggccattacc atgctgacag ccagagggat 1380
tatccggttt gtcatggct ttagcttgcc gatgtccatt gttgcacatct gctatgggct 1440
cattgcagcc aagatccaca aaaagggcat gattaaatcc agccgtccct tacgggtct 1500
cactgtgtg gtggcttctt tttcatctg ttggttccc tttcaactgg ttgccttct 1560
gggcacccgtc tggctcaaag agatgttggt ctatggcaag tacaaaatca ttgacatcct 1620
ggtaaccca acgagctccc tggcattctt caacagctgc ctcaacccca tgctttacgt 1680
ctttgtgggc caagacttcc gagagagact gatccactcc ctgcccacca gtctggagag 1740
ggccctgtct gaggactcag ccccaactaa tgacacggct gccaattctg ctccacctcc 1800
tgcaagact gagttacagg caatgtgagg atggggtcag ggatattttg agttctgttc 1860
atccctaccct aatgccagtt ccagcttcat ctacccttga gtcatttgc ggcattcaag 1920
gatgcacagc tcaagtattt attcaggaaa aatgctttt tgccctgtat ttggggctaa 1980
gaaatagaca gtcaggctac taaaatatta gtgttatttt ttgtttttt acttctgcct 2040
ataccctggg gtaagtggag ttggaaata caagaagaga aagaccagtg gggatttgc 2100
agacttagat gagatagcgc ataataaggg gaagacttta aagtataaag taaaatgttt 2160
gctgttaggtt ttttatactt attaaaaaaa atcagattat ggaagtttc ttcttatttt 2220
agtttgcataa gagtttctg ttctttttc ttacatcatg atgtgacttt gcattttatc 2280
aaatgcattt tctacatgtt ttaagatgtt catattttc ttcttctttt atgtaaatca 2340
ttataaataa tggcattaa gttctgaatg taaaactact ctggaaattcc tggaaataaac 2400
cacacttagt cctgtatgtac tttaaatatt tataatctac aggagttgggt tagaatttct 2460
gtgttatgt ttatatactg ttatctactt ttgttctacta tccttgctaa gtttcatag 2520
aaaataagga acaaagagaa acttgtaaatg gtctctgaaa aggaatttgag aagtaattcc 2580

tctgattctg tttctggtg ttatatctt attaaatatt cagaaaaatt c

2631

<210> 2
<211> 351
<212> PRT
<213> human neutrophils and monocytes

<400> 2

Met Glu Thr Asn Phe Ser Thr Pro Leu Asn Glu Tyr Glu Glu Val Ser
1 5 10 15

Tyr Glu Ser Ala Gly Tyr Thr Val Leu Arg Ile Leu Pro Leu Val Val
20 25 30

Leu Gly Val Thr Phe Val Leu Gly Val Leu Gly Asn Gly Leu Val
35 40 45

Ile Trp Val Ala Gly Phe Arg Met Thr Arg Thr Val Thr Thr Ile Cys
50 55 60

Tyr Leu Asn Leu Ala Leu Ala Asp Phe Ser Phe Thr Ala Thr Leu Pro
65 70 75 80

Phe Leu Ile Val Ser Met Ala Met Gly Glu Lys Trp Pro Phe Gly Trp
85 90 95

Phe Leu Cys Lys Leu Ile His Ile Val Val Asp Ile Asn Leu Phe Gly
100 105 110

Ser Val Phe Leu Ile Gly Phe Ala Leu Asp Arg Cys Ile Cys Val Leu
115 120 125

His Pro Val Trp Ala Gln Asn His Arg Thr Val Ser Leu Ala Met Lys
130 135 140

Val Ile Val Gly Pro Trp Ile Leu Ala Leu Val Leu Thr Leu Pro Val
145 150 155 160

Phe Leu Phe Leu Thr Thr Val Thr Ile Pro Asn Gly Asp Thr Tyr Cys
165 170 175

Thr Phe Asn Phe Ala Ser Trp Gly Gly Thr Pro Glu Glu Arg Leu Lys
180 185 190

Val Ala Ile Thr Met Leu Thr Ala Arg Gly Ile Ile Arg Phe Val Ile
195 200 205

Gly Phe Ser Leu Pro Met Ser Ile Val Ala Ile Cys Tyr Gly Leu Ile
210 215 220

Ala Ala Lys Ile His Lys Lys Gly Met Ile Lys Ser Ser Arg Pro Leu
225 230 235 240

Arg Val Leu Thr Ala Val Ala Ser Phe Phe Ile Cys Trp Phe Pro
245 250 255

Phe Gln Leu Val Ala Leu Leu Gly Thr Val Trp Leu Lys Glu Met Leu
260 265 270

Phe Tyr Gly Lys Tyr Lys Ile Ile Asp Ile Leu Val Asn Pro Thr Ser
275 280 285

Ser Leu Ala Phe Phe Asn Ser Cys Leu Asn Pro Met Leu Tyr Val Phe
290 295 300

Val Gly Gln Asp Phe Arg Glu Arg Leu Ile His Ser Leu Pro Thr Ser
305 310 315 320

Leu Glu Arg Ala Leu Ser Glu Asp Ser Ala Pro Thr Asn Asp Thr Ala
325 330 335

Ala Asn Ser Ala Ser Pro Pro Ala Glu Thr Glu Leu Gln Ala Met
340 345 350

33998-705.831 seq listing_ST25.txt
SEQUENCE LISTING

<110> Nash, Norman
Scully, Audra
Gardell, Luis
Olsson, Roger
Gustafsson, Magnus

<120> USE OF LIPOXIN RECEPTOR, FPRL1, AS A TOOL FOR IDENTIFYING COMPOUNDS EFFECTIVE IN THE TREATMENT OF PAIN AND INFLAMMATION

<130> 33998-705.831

<140> US 10/590,001
<141> 2006-08-17

<150> PCT/US2004/036952
<151> 2004-11-04

<160> 2

<170> PatentIn version 3.4

<210> 1
<211> 2631
<212> DNA
<213> Homo sapiens

<400> 1
ggcacgagga acaacctatt tgcaaagttg gcgcaaacat tcctgcctga caggaccatg 60
gacacaggtt gtagagatag agatggctct ggctgtgcat tcagcagatt ctgtagatag 120
aattaatagg acttggatgg gattgtggtg agagaaagtg aaatgaaaga taagttctag 180
tttggaaagtt ttaacaactg aatgtttaaa ctcaaataaga cacaaaatat tggaaagatg 240
gcaggttgg gaggatgaga caatcaactg tttggtttag ccacgttagg tttgaaatgt 300
ctacgggatc ccgtggggag aggttatatc agactggagc accagagaga ggccaaggct 360
gatagtttag atgaaaagag agcatgatat ttaagccct gagactggat aatatcacct 420
atagaaagac tatatagaga taagagaggt gggaaacaag taaaagctgc gggacactcc 480
taaatttaga gtcaaattta gagcagaaaa tactagcaaa gggactgaa aagcggtggc 540
caattgagct tcaaattgcaa gtgaaagtgt gttgtgtta catttatcat ctcatggcac 600
aggaaaaacg tgatttaagg agaaggaagc gatccatgg gaagaagaga tccatggat 660
cctctatcac gaagatattg agataagaac caatatggat ttgcacccac tgcatttgca 720
gccttgaggt cataagcatc ctcagaaaa tgcaccaggt gctgctggca agatggaaac 780
caacttctcc actcctctga atgaatatga agaagtgtcc tatgagtctg ctggctacac 840
tgttctgcgg atcctccat tgggtggct tgggttcacc tttgtcctcg gggcctggg 900
caatggcctt gtgatctggg tggctggatt ccggatgaca cgacagtc acaccatctg 960
ttacctgaac ctggccctgg ctgactttc tttcacggcc acattaccat tcctcattgt 1020

33998-705.831 seq listing_ST25.txt

ctccatggcc	atgggagaaa	aatggcctt	tggctggttc	ctgtgttgt	taattcacat	1080
cgtggtggac	atcaacctct	ttggaagtgt	cttcttgatt	ggtttcattg	cactggaccg	1140
ctgcatttgt	gtcctgcac	cagtcgggc	ccagaaccac	cgcactgtga	gtctggccat	1200
gaaggtgatc	gtcggacctt	ggattcttgc	tctagtcctt	accttgcag	tttccctctt	1260
tttgactaca	gtaactatta	caaattggga	cacatcatgt	acttcaact	ttgcattctg	1320
gggtggcacc	cctgaggaga	ggctgaaggt	ggccattacc	atgctgacag	ccagaggat	1380
tatccggttt	gtcattggct	ttagcttgcc	gatgtccatt	gttgcattct	gctatggct	1440
cattgcagcc	aagatccaca	aaaagggcat	gattaaatcc	agccgtccct	tacgggtcct	1500
caactgctgt	gtggcttctt	tcttcatctg	ttggtttccc	tttcaactgg	ttgcccctct	1560
gggcaccgtc	tggctcaaag	agatgttgg	ctatggcaag	tacaaaatca	ttgacatcct	1620
ggtaaccca	acgagctccc	tggcattctt	caacagctgc	ctcaacccca	tgctttacgt	1680
ctttgtggc	caagacttcc	gagagagact	gatccactcc	ctgcccacca	gtctggagag	1740
ggccctgtct	gaggactcag	ccccaaactaa	tgacacggct	gccaattctg	cttcacccct	1800
tgcagagact	gagttacagg	caatgtgagg	atggggtcag	ggatattttg	agttctgttc	1860
atcctaccct	aatgccagtt	ccagcttcat	ctacccttga	gtcatattga	ggcattcaag	1920
gatgcacagc	tcaagtattt	attcaggaaa	aatgctttt	tgtccctgat	ttggggctaa	1980
gaaatagaca	gtcaggctac	taaaatatta	gtgttatttt	ttgttttttg	acttctgcct	2040
ataccctggg	gtaagtggag	ttggaaata	caagaagaga	aagaccagt	gggatttgta	2100
agacttagat	gagatagcgc	ataataaggg	gaagacttta	aagtataaag	taaaatgttt	2160
gctgttagtt	ttttatagct	attaaaaaaa	atcagattat	ggaagttttc	ttctattttt	2220
agtttgctaa	gagtttctg	tttcttttc	ttacatcatg	atgtgacttt	gcattttatc	2280
aaatgcattt	tctacatgta	ttaagatggt	catattattc	ttcttctttt	atgtaaatca	2340
ttataaataa	tgttcattaa	gttctgaatg	ttaaactact	tttgaattcc	tggaaataaac	2400
cacacttagt	cctgatgtac	tttaaatatt	tatatctcac	aggagttgg	tagaatttct	2460
gtgtttatgt	ttatatactg	ttatctact	ttttctacta	tccttgctaa	gttttcatag	2520
aaaataagga	acaaagagaa	acttgaatg	gtctctgaaa	aggaatttgag	aagtaattcc	2580
tctgattctg	ttttctgggt	ttatatcttt	attaaatatt	cagaaaaatt	c	2631

<210> 2
<211> 351
<212> PRT
<213> Homo sapiens

<400> 2

Met Glu Thr Asn Phe Ser Thr Pro Leu Asn Glu Tyr Glu Glu Val Ser
Page 2

33998-705.831 seq listing_ST25.txt

1

5

10

15

Tyr Glu Ser Ala Gly Tyr Thr Val Leu Arg Ile Leu Pro Leu Val Val
20 25 30

Leu Gly Val Thr Phe Val Leu Gly Val Leu Gly Asn Gly Leu Val Ile
35 40 45

Trp Val Ala Gly Phe Arg Met Thr Arg Thr Val Thr Thr Ile Cys Tyr
50 55 60

Leu Asn Leu Ala Leu Ala Asp Phe Ser Phe Thr Ala Thr Leu Pro Phe
65 70 75 80

Leu Ile Val Ser Met Ala Met Gly Glu Lys Trp Pro Phe Gly Trp Phe
85 90 95

Leu Cys Lys Leu Ile His Ile Val Val Asp Ile Asn Leu Phe Gly Ser
100 105 110

Val Phe Leu Ile Gly Phe Ile Ala Leu Asp Arg Cys Ile Cys Val Leu
115 120 125

His Pro Val Trp Ala Gln Asn His Arg Thr Val Ser Leu Ala Met Lys
130 135 140

Val Ile Val Gly Pro Trp Ile Leu Ala Leu Val Leu Thr Leu Pro Val
145 150 155 160

Phe Leu Phe Leu Thr Thr Val Thr Ile Pro Asn Gly Asp Thr Tyr Cys
165 170 175

Thr Phe Asn Phe Ala Ser Trp Gly Gly Thr Pro Glu Glu Arg Leu Lys
180 185 190

Val Ala Ile Thr Met Leu Thr Ala Arg Gly Ile Ile Arg Phe Val Ile
195 200 205

Gly Phe Ser Leu Pro Met Ser Ile Val Ala Ile Cys Tyr Gly Leu Ile
210 215 220

Ala Ala Lys Ile His Lys Lys Gly Met Ile Lys Ser Ser Arg Pro Leu
225 230 235 240

Arg Val Leu Thr Ala Val Val Ala Ser Phe Phe Ile Cys Trp Phe Pro
245 250 255

33998-705.831.seq.listing_ST25.txt

Phe Gln Leu Val Ala Leu Leu Gly Thr Val Trp Leu Lys Glu Met Leu
260 265 270

Phe Tyr Gly Lys Tyr Lys Ile Ile Asp Ile Leu Val Asn Pro Thr Ser
275 280 285

Ser Leu Ala Phe Phe Asn Ser Cys Leu Asn Pro Met Leu Tyr Val Phe
290 295 300

Val Gly Gln Asp Phe Arg Glu Arg Leu Ile His Ser Leu Pro Thr Ser
305 310 315 320

Leu Glu Arg Ala Leu Ser Glu Asp Ser Ala Pro Thr Asn Asp Thr Ala
325 330 335

Ala Asn Ser Ala Ser Pro Pro Ala Glu Thr Glu Leu Gln Ala Met
340 345 350